# Shaquille O'Neal Credits Zepbound for Sleep Apnea Improvement and Weight Loss
Basketball legend Shaquille O'Neal recently disclosed that the injectable weight-loss medication Zepbound helped him address both sleep apnea and excess weight. The drug, which contains semaglutide, belongs to a class of medications called GLP-1 receptor agonists originally developed for type 2 diabetes management.
Sleep apnea occurs when airways collapse repeatedly during sleep, disrupting breathing and preventing restorative rest. Excess weight is a primary risk factor for the condition. O'Neal's experience reflects what researchers have observed across clinical trials. GLP-1 medications like Zepbound work by slowing stomach emptying and signaling fullness to the brain, leading to reduced food intake and significant weight loss over time.
The connection between weight reduction and sleep apnea improvement is well-established in medical research. Studies show that even modest weight loss of 5-10 percent can measurably improve sleep apnea symptoms. When patients lose larger amounts of weight, the improvement becomes more dramatic.
O'Neal's public disclosure adds to growing evidence that GLP-1 medications address metabolic conditions beyond diabetes. The FDA approved Zepbound specifically for weight management in adults with obesity or those overweight with weight-related health complications like sleep apnea.
However, these medications require medical supervision. Common side effects include nausea, vomiting, and constipation. More serious complications, though rare, can include pancreatitis and gallbladder problems. They also carry a significant price tag, typically costing hundreds of dollars monthly without insurance coverage.
O'Neal's case highlights how treating one health condition can have cascading benefits. Reducing his weight through Zepbound treatment improved his sleep quality by addressing the underlying